(Sharecast News) - Eli Lilly reported the first successful phase three results for retatrutide, its experimental once-weekly 'triple agonist' drug, showing unprecedented weight loss alongside major improvements in knee osteoarthritis pain.
The company said the findings from the TRIUMPH-4 trial positioned retatrutide as a potential new option for people with obesity...

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE